Who this is for
This page is for people with hormone receptor–positive, HER2-negative early breast cancer who have been told their cancer is “high risk,” even after surgery.
If you were expecting to take hormone therapy alone and then move on with life, being told you may need additional treatment can feel unexpected and discouraging. The reason is not that something has gone wrong. It is because we now understand risk more precisely — and for some patients, adding treatment early can meaningfully reduce the chance of recurrence.
Why this question arises
Hormone receptor–positive, HER2-negative breast cancer is often described as the “more favourable” subtype.
For many women, surgery followed by endocrine therapy (such as tamoxifen or an aromatase inhibitor) is sufficient.
However, we now know that not all hormone receptor–positive cancers behave the same way. A subgroup — particularly those with multiple positive lymph nodes, large tumours, or high tumour grade — carries a significantly higher risk of recurrence despite hormone therapy.
The monarchE trial changed how we approach this group.
What monarchE studied
monarchE was a large international phase III clinical trial evaluating whether adding abemaciclib (a CDK4/6 inhibitor) to standard endocrine therapy could reduce recurrence risk in high-risk early breast cancer.
Who was included:
• Hormone receptor–positive
• HER2-negative
• Node-positive early breast cancer
• High-risk features (e.g., ≥4 positive nodes, or 1–3 nodes with high grade or large tumour)
This is important: this treatment is not for all early breast cancer. It is specifically for higher-risk biology.
Key statistical results
• Invasive disease-free survival hazard ratio: 0.66
• Absolute improvement in 4-year invasive disease-free survival: approximately 6–7%
• Reduction in distant recurrence risk: hazard ratio approximately 0.65
What this means
A hazard ratio of 0.66 means there was roughly a 34% relative reduction in the risk of recurrence compared with endocrine therapy alone.
The absolute benefit depends on baseline risk. For patients at higher risk, this reduction can be clinically meaningful.
This is not about treating everyone more aggressively. It is about identifying the group where early intensification reduces long-term recurrence.
Why this matters in Melbourne and Australia
In Australia, abemaciclib is PBS-listed for eligible high-risk early breast cancer patients based on monarchE criteria.
That means access is structured and criteria-based. It is not automatic — and careful risk assessment is essential.
In Melbourne, treatment discussions often involve reviewing:
• Number of positive lymph nodes
• Tumour size and grade
• Ki-67 (where relevant)
• Overall health and tolerance
The decision is individualised.
Side effects and practical considerations
Abemaciclib is taken orally for two years alongside endocrine therapy.
The most common side effect is diarrhoea, particularly early in treatment. This is usually manageable with dose adjustment and supportive medication.
Other possible effects include fatigue and mild blood count suppression.
The key question is whether the expected reduction in recurrence risk outweighs the side-effect burden for the individual patient.
International patients, including Sri Lanka
Patients from Sri Lanka and other countries sometimes seek clarification regarding whether they meet high-risk criteria under monarchE and whether similar treatment strategies are available locally.
In some settings, access may differ depending on healthcare systems. A structured review of pathology and nodal status can clarify eligibility and risk category.
How this fits into modern breast cancer care
The monarchE trial reflects a broader shift in oncology: we are moving from treating by stage alone to treating by risk biology.
For some patients, hormone therapy alone remains entirely appropriate.
For others, adding a CDK4/6 inhibitor early may reduce recurrence risk in a meaningful way.
The goal is not more treatment for everyone.
The goal is the right treatment for the right group.
Key Takeaway
• Some high-risk early breast cancers benefit from adding abemaciclib to hormone therapy.
• monarchE showed a meaningful reduction in recurrence risk (hazard ratio 0.66).
• Treatment decisions should be individualised based on nodal status, tumour biology and patient preference.